Skip to main content
52°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Johnson & Johnson
(NY:
JNJ
)
167.36
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Johnson & Johnson
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem
Today 7:55 EDT
Johnson & Johnson and Altria Group are two prominent dividend stocks, but I wouldn't rely on their payouts.
Via
The Motley Fool
Court Orders Johnson & Johnson To Compensate Auris Health Shareholders $1B
September 04, 2024
Johnson & Johnson is ordered to pay $1 billion in damages to Auris Health shareholders for breaching a 2019 merger agreement. The ruling finds Johnson & Johnson failed to support critical technology,...
Via
Benzinga
3 Dividend Stocks to Double Up on Right Now
September 04, 2024
These companies have excellent records of growing their dividends.
Via
The Motley Fool
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Critical Insights From Johnson & Johnson Analyst Ratings: What You Need To Know
September 03, 2024
Via
Benzinga
Analyzing NYSE:JNJ's Dividend Potential.
September 02, 2024
Why JOHNSON & JOHNSON (NYSE:JNJ) qualifies as a good dividend investing stock.
Via
Chartmill
Will JOHNSON & JOHNSON Break Out? A Technical Analysis Perspective.
August 30, 2024
A technical analysis of JOHNSON & JOHNSON (NYSE:JNJ) shows it may be setting up for a breakout.
Via
Chartmill
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
August 29, 2024
Via
Benzinga
Is Johnson & Johnson the Best Dividend Stock for You?
September 01, 2024
You won't find a more dependable dividend payer on Wall Street. But whether it's the best stock for you depends on other factors.
Via
The Motley Fool
Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.
September 01, 2024
Via
The Motley Fool
Johnson & Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol 'Rapid Release' Gelcaps
August 30, 2024
Kenvue defends against a consumer lawsuit alleging that its Tylenol "Rapid Release" gelcaps did not relieve pain faster than regular tablets. A federal judge ruled the claims were preempted by FDA...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Elliott Wave Technical Analysis: Johnson & Johnson - Friday, Aug. 30
August 30, 2024
JNJ appears to be in the latter stages of wave {iii} of 1.
Via
Talk Markets
Johnson & Johnson's Golden Cross: A Bullish Prescription For Investors?
August 29, 2024
Johnson & Johnson (NYSE:JNJ) achieves Golden Cross, signaling shift to bullish trend. Stock at $164.43, above all key moving averages & with positive catalysts ahead.
Via
Benzinga
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
August 28, 2024
Via
Benzinga
Is Johnson & Johnson Stock a Buy?
August 25, 2024
The company hasn't performed well in recent years,
Via
The Motley Fool
Johnson & Johnson Unusual Options Activity
August 19, 2024
Via
Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
August 29, 2024
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows...
Via
Benzinga
Exposures
Product Safety
12 Dividend Stocks to Earn Income Every Month
August 28, 2024
Get paid a dividend on a monthly basis.
Via
The Motley Fool
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
August 27, 2024
There's no reason to succumb to gloom and doom here.
Via
The Motley Fool
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
August 27, 2024
Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatment. Addex could receive up to $330 million plus royalties under the...
Via
Benzinga
Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods
August 27, 2024
Cramer gives his take on E.l.f Beauty, Acadia Pharmaceuticals, B&G Foods, Lucid, SoFi, Dell, Johnson & Johnson, UWM and Symbotic.
Via
Benzinga
Here Are 2 Great Vanguard Dividend ETFs: Which Is Right For You?
August 27, 2024
Now could be a great time to buy excellent dividend stocks, but these two ETFs have different approaches.
Via
The Motley Fool
Topics
ETFs
Meet Wall Street's Safest Dividend Stock: A Small-Cap Company Few Investors Know Exists
August 27, 2024
This relative unknown hasn't missed a dividend payment to its shareholders in more than 200 years!
Via
The Motley Fool
Johnson & Johnson Aims New Policy For Hospital Payments Under 340B Drug Discount Program Related To Its Flagship Blood Thinner And Arthritis Drugs
August 26, 2024
Johnson & Johnson announced major changes to its 340B pricing for Stelara and Xarelto, effective October 15. Disproportionate share hospitals will need to purchase these drugs at full price initially...
Via
Benzinga
Johnson & Johnson Seeks Resolution With Plaintiffs, Pushes To Finalize $6.5B Talc Settlement
August 26, 2024
Johnson & Johnson is negotiating with plaintiffs' lawyers opposing its $6.48 billion talc settlement,
Via
Benzinga
2 Unstoppable Stocks That Are Screaming Buys in August
August 26, 2024
These stocks have quality businesses behind them.
Via
The Motley Fool
Donald Trump Owns These 21 Dividend Kings. Should You?
August 26, 2024
Some of Trump's Dividend Kings deserve a crown more than others.
Via
The Motley Fool
Topics
Government
Exposures
Political
A Big CEO Move, Big Buffett Buys, and More
August 22, 2024
Motley Fool analysts talk over market news including earnings updates from Home Depot, Walmart, and Brinker.
Via
The Motley Fool
This Undervalued Stock Could Join the Race With Eli Lilly to the $1 Trillion Club
August 22, 2024
This leading pharmaceutical stock is flying under the radar right now.
Via
The Motley Fool
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
August 20, 2024
Johnson & Johnson to acquire V-Wave for $600 million with potential $1.1 billion in milestone payments. Deal boosts JNJ MedTech's cardiovascular portfolio. Also, FDA approves Rybrevant-Lazcluze combo...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.